Granulocyte Colony-Stimulating Factor Receptor Mutations in Myeloid Malignancy
نویسندگان
چکیده
منابع مشابه
Granulocyte Colony-Stimulating Factor Receptor Mutations in Myeloid Malignancy
Granulocyte colony-stimulating factor is a cytokine able to stimulate both myelopoiesis and hematopoietic stem cell mobilization, which has seen it used extensively in the clinic to aid hematopoietic recovery. It acts specifically via the homodimeric granulocyte colony-stimulating factor receptor (G-CSFR), which is principally expressed on the surface of myeloid and hematopoietic progenitor cel...
متن کاملGranulocyte colony-stimulating factor and its receptor.
Granulocyte colony-stimulating factor (G-CSF) is a glycoprotein of Mr of about 20,000, which stimulates proliferation and differentiation of progenitor cells of neutrophils. Recent clinical application of G-CSF has proven that this hormone is effective in treatment of patients suffering from neutropenia. In the last few years, the biochemical and molecular nature of the G-CSF receptor has been ...
متن کاملGranulocyte colony-stimulating factor.
In the background section of their abstract, Woei-Cherng Shyu and associates state that because granulocyte colony-stimulating factor (G-CSF) has anti-inflammatory and neuroprotective properties and the capacity to mobilize stem cells, it has the potential to be used in treatment of stroke. However, there are limited data about the effects of G-CSF on hemostasis. It has been suggested that G-CS...
متن کاملGranulocyte colony stimulating factor.
Granulocyte colony-stimulating factor was discovered during attempts to define the normal regulators present in cell supernatants that could induce terminal differentiation of the murine myeloid leukemic cell line WEHI-3B D+. The purification and subsequent cloning of both murine and human G-CSF allowed the normal functions of this molecule to be elucidated and indicated that it was a relativel...
متن کاملGranulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment.
Event-free survival for children with acute lymphoblastic leukemia (ALL) now exceeds 80% in the most effective trials. Failures are due to relapse, toxicity, and second cancers such as therapy-related myeloid leukemia or myelodysplasia (t-ML). Topoisomerase II inhibitors and alkylators can induce t-ML; additional risk factors for t-ML remain poorly defined. The occurrence of t-ML among children...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Frontiers in Oncology
سال: 2014
ISSN: 2234-943X
DOI: 10.3389/fonc.2014.00093